CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 203 enrolled
Drug / intervention
[18F] Flutemetamoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01165554
NCT01165554Phase 3Completed
CompareCT.gov

A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem

GE Healthcare·interventional·Posted Jul 20, 2010·Updated Dec 4, 2013

In Brief

A Phase 3 clinical trial evaluating [18F] Flutemetamol for Brain Fibrillarab Levels. Completed, enrolled 203 participants across 1 site.

Detailed Summary

To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Fibrillarab Levels
CountriesUnited States
Collaboratorsi3 Statprobe, Covance

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 20, 2010
Enrollment StartMay 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.0 years ago

Interventions

[18F] Flutemetamoldrug

Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.